|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
BioMimetic Therapeutics, Inc. (BMTI) to Sell Remaining Dental Business for Additional $40 Million Cash plus Continuation of Royalties
12/18/2007 12:08:41 PM
FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced the Company has entered into a definitive agreement with Luitpold Pharmaceuticals Inc., under which it will sell its remaining dental business, including the downstream formulation, fill and finish manufacturing rights of GEM 21S®, to Luitpold. Luitpold currently markets the GEM 21S product through its Osteohealth Company division. The transaction is expected to close on or about January 4, 2008. The Company will receive $40 Million in cash as a result of the transaction, plus approximately $4 million in cash from the sale of existing inventory, and royalty payments based on net sales of GEM 21S and future products in the dental and cranio-maxillofacial field. BioMimetic will receive the cash from this sale in four installments with $30 Million paid not later than 60 days of the close of the transaction, $6 Million paid not later than 18 months from close and the remaining $4 Million to be paid no later than year-end 2009.
|
|
|
|
|
|
|
|
|
|
|